TrialNet Abatacept Prevention Study
Study Name: CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At-Risk for Type 1 Diabetes Mellitus
Principal Investigator: Carla Greenbaum, MD
What is the Abatacept prevention trial?
The investigators carrying out this study are part of a research group called TrialNet that is studying type 1 diabetes. These investigators are testing an investigational drug, called abatacept [CTLA4], which is approved by the U.S. Food and Drug Administration as a treatment for rheumatoid arthritis and polyarticular juvenile idiopathic arthritis (JIA) in pediatric patients 6 years of age and older. In a previous TrialNet study, abatacept was shown to have some effect on preserving insulin secretion after diagnosis, which is why it is now being tested in prevention.
Who can participate?
- Individuals who are 6 and older with two autoantibodies and normal glucose tolerance.
- All participants are identified through the TrialNet Pathway to Prevention study.
What will study participants be asked to do?
This placebo-controlled study will have two phases, a treatment phase for the first year and then a monitoring phase. During the treatment phase, you will receive the study drug 14 times over the first year. During the monitoring phase, you will have visits every six months.
Read the consent form here:Abatacept Intervention Consent Form